A dual-modality herpes simplex virus 2 vaccine for preventing genital herpes by using glycoprotein C and D subunit antigens to induce potent antibody responses and adenovirus vectors containing capsid and tegument proteins as T cell immunogens

Journal of Virology

Volumn 89, Issue 16, 2015, Pages 8497-8509

  Awasthi, Sita ^a   Mahairas, Gregory G ^b   Shaw, Carolyn E ^a   Huang, Meei Li ^b   Koelle, David M ^b,c   Posavad, Christine ^b,c   Corey, Lawrence ^b,c   Friedman, Harvey M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM POTASSIUM SULFATE; CAPSID PROTEIN; CAPSID PROTEIN VP5; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; NEUTRALIZING ANTIBODY; PROTEIN C; TEGUMENT PROTEIN VP 13 14; UNCLASSIFIED DRUG; VIRUS DNA; GLYCOPROTEIN C, HERPES SIMPLEX VIRUS TYPE 2; GLYCOPROTEIN D-HERPES SIMPLEX VIRUS TYPE 2; PRIMER DNA; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACULOVIRIDAE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; SPINAL GANGLION; VIRUS SHEDDING; ADENOVIRIDAE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; HERPES GENITALIS; IMMUNOLOGY; MOUSE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALIA; CAVIA; HUMAN HERPESVIRUS 2; MIRIDAE; MURINAE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BLOTTING, WESTERN; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; GUINEA PIGS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84938151517     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01089-15     Document Type: Article

References (79)

1. Looker KJ, Garnett GP, Schmid GP. 2008. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86:805-812. http://dx.doi.org/10.2471/BLT.07.046128.
2. Corey L, Adams HG, Brown ZA, Holmes KK. 1983. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 98:958-972. http://dx.doi.org/10.7326/0003-4819-98-6-958.
3. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. 1992. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 116:197-202. http://dx.doi.org/10.7326/0003-4819-116-3-197.
4. Koutsky LA, Stevens CE, Holmes KK, Ashley RL, Kiviat NB, Critchlow CW, Corey L. 1992. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 326:1533-1539. http://dx.doi.org/10.1056/NEJM199206043262305.
5. Brown ZA, Vontver LA, Benedetti J, Critchlow CW, Sells CJ, Berry S, Corey L. 1987. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med 317:1246-1251. http://dx.doi.org/10.1056/NEJM198711123172002.
6. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, Watts DH, Berry S, Herd M, Corey L. 1997. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 337:509-515. http://dx.doi.org/10.1056/NEJM199708213370801.
7. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, de Sierra TM, Weller S, Soong SJ, Kiell J, Lakeman FD, Whitley RJ, National Institute of Allergy Infectious Diseases Collaborative Antiviral Study Group. 2001. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108:230-238. http://dx.doi.org/10.1542/peds.108.2.230.
8. Reynolds SJ, Risbud AR, Shepherd ME, Zenilman JM, Brookmeyer RS, Paranjape RS, Divekar AD, Gangakhedkar RR, Ghate MV, Bollinger RC, Mehendale SM. 2003. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 187:1513-1521. http://dx.doi.org/10.1086/368357.
9. Renzi C, Douglas JM, Jr, Foster M, Critchlow CW, Ashley-Morrow R, Buchbinder SP, Koblin BA, McKirnan DJ, Mayer KH, Celum CL. 2003. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. J Infect Dis 187:19-25. http://dx.doi.org/10.1086/345867.
10. Wald A, Link K. 2002. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185:45-52. http://dx.doi.org/10.1086/338231.
11. Schacker T, Zeh J, Hu HL, Hill E, Corey L. 1998. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 178: 1616-1622. http://dx.doi.org/10.1086/314486.
12. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM, Jr, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M, Valacyclovir HSV Transmission Study Group. 2004. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350:11-20. http://dx.doi.org/10.1056/NEJMoa035144.
13. Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD, Johnson BL, Wiesmeier E, Growdon W, Creagh-Kirk T, Keeney R. 1983. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med 308:916-921.
14. Sawtell NM, Bernstein DI, Stanberry LR. 1999. A temporal analysis of acyclovir inhibition of induced herpes simplex virus type 1 in vivo reactivation in the mouse trigeminal ganglia. J Infect Dis 180:821-823. http://dx.doi.org/10.1086/314958.
15. Sawtell NM, Thompson RL, Stanberry LR, Bernstein DI. 2001. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis 184:964-971. http://dx.doi.org/10.1086/323551.
16. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, Deal CD. 2014. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 209:828-836. http://dx.doi.org/10.1093/infdis/jit651.
17. Awasthi S, Friedman HM. 2014. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus 1 genital herpes. J Infect Dis 209:813-815. http://dx.doi.org/10.1093/infdis/jit658.
18. Seidel-Dugan C, Ponce de Leon M, Friedman HM, Fries LF, Frank MM, Cohen GH, Eisenberg RJ. 1988. C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2. J Virol 62:4027-4036.
19. Hung SL, Peng C, Kostavasili I, Friedman HM, Lambris JD, Eisenberg RJ, Cohen GH. 1994. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology 203:299-312. http://dx.doi.org/10.1006/viro.1994.1488.
20. Rux AH, Lou H, Lambris JD, Friedman HM, Eisenberg RJ, Cohen GH. 2002. Kinetic analysis of glycoproteinCof herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b. Virology 294:324-332. http://dx.doi.org/10.1006/viro.2001.1326.
21. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM. 1986. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol 137:1636-1641.
22. Eisenberg RJ, Ponce de Leon M, Friedman HM, Fries LF, Frank MM, Hastings JC, Cohen GH. 1987. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog 3:423-435. http://dx.doi.org/10.1016/0882-4010(87)90012-X.
23. Hook LM, Lubinski JM, Jiang M, Pangburn MK, Friedman HM. 2006. Herpes simplex virus type 1 and 2 glycoprotein C prevents complementmediated neutralization induced by natural immunoglobulin M antibody. J Virol 80:4038-4046. http://dx.doi.org/10.1128/JVI.80.8.4038-4046.2006.
24. Harris SL, Frank I, Yee A, Cohen GH, Eisenberg RJ, Friedman HM. 1990. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Infect Dis 162:331-337. http://dx.doi.org/10.1093/infdis/162.2.331.
25. Awasthi S, Lubinski JM, Friedman HM. 2009. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine 27:6845-6853. http://dx.doi.org/10.1016/j.vaccine.2009.09.017.
26. Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. 2011. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 85:10472-10486. http://dx.doi.org/10.1128/JVI.00849-11.
27. Judson KA, Lubinski JM, Jiang M, Chang Y, Eisenberg RJ, Cohen GH, Friedman HM. 2003. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J Virol 77: 12639-12645. http://dx.doi.org/10.1128/JVI.77.23.12639-12645.2003.
28. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. 2001. Differential roles of B cells and IFN-γ-secreting CD4+T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol 82:845-853.
29. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 101: 1500-1508. http://dx.doi.org/10.1172/JCI1758.
30. Verjans GM, Hintzen RQ, van Dun JM, Poot A, Milikan JC, Laman JD, Langerak AW, Kinchington PR, Osterhaus AD. 2007. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A 104:3496-3501. http://dx.doi.org/10.1073/pnas.0610847104.
31. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L. 2007. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204:595-603. http://dx.doi.org/10.1084/jem.20061792.
32. Mikloska Z, Ruckholdt M, Ghadiminejad I, Dunckley H, Denis M, Cunningham AL. 2000. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 164: 5167-5176. http://dx.doi.org/10.4049/jimmunol.164.10.5167.
33. + T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 68:2803-2810.
34. Koelle DM, Frank JM, Johnson ML, Kwok WW. 1998. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol 72:7476-7483.
35. Koelle DM, Schomogyi M, McClurkan C, Reymond SN, Chen HB. 2000. CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins. J Virol 74:11422-11425. http://dx.doi.org/10.1128/JVI.74.23.11422-11425.2000.
36. Posavad CM, Wald A, Hosken N, Huang ML, Koelle DM, Ashley RL, Corey L. 2003. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity? J Immunol 170:4380-4388. http://dx.doi.org/10.4049/jimmunol.170.8.4380.
37. + T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 80:5509-5515. http://dx.doi.org/10.1128/JVI.02659-05.
38. Skoberne M, Cardin R, Lee A, Kazimirova A, Zielinski V, Garvie D, Lundberg A, Larson S, Bravo FJ, Bernstein DI, Flechtner JB, Long D. 2013. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs. J Virol 87:3930-3942. http://dx.doi.org/10.1128/JVI.02745-12.
39. Posavad CM, Koelle DM, Shaughnessy MF, Corey L. 1997. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 94:10289-10294. http://dx.doi.org/10.1073/pnas.94.19.10289.
40. Posavad CM, Wald A, Kuntz S, Huang ML, Selke S, Krantz E, Corey L. 2004. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 190:693-696. http://dx.doi.org/10.1086/422755.
41. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. 1998. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280:61-66. http://dx.doi.org/10.1001/jama.280.1.61.
42. Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. 2003. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 18:593-603. http://dx.doi.org/10.1016/S1074-7613(03)00112-2.
43. Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL. 2000. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 191:1459-1466. http://dx.doi.org/10.1084/jem.191.9.1459.
44. Liu T, Tang Q, Hendricks RL. 1996. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J Virol 70:264-271.
45. + cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J Virol 70:8165-8168.
46. Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L. 2001. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol 166:4049-4058. http://dx.doi.org/10.4049/jimmunol.166.6.4049.
47. Koelle DM, Liu Z, McClurkan CM, Topp MS, Riddell SR, Pamer EG, Johnson AS, Wald A, Corey L. 2002. Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 110:537-548.
48. Koelle DM, Liu Z, McClurkan CL, Cevallos RC, Vieira J, Hosken NA, Meseda CA, Snow DC, Wald A, Corey L. 2003. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissuespecific homing receptor. Proc Natl Acad Sci U S A 100:12899-12904. http://dx.doi.org/10.1073/pnas.2131705100.
49. Tal-Singer R, Peng C, Ponce De Leon M, Abrams WR, Banfield BW, Tufaro F, Cohen GH, Eisenberg RJ. 1995. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol 69:4471-4483.
50. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. 2006. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 80:5283-5291. http://dx.doi.org/10.1128/JVI.02013-05.
51. Canziani G, Zhang W, Cines D, Rux A, Willis S, Cohen G, Eisenberg R, Chaiken I. 1999. Exploring biomolecular recognition using optical biosensors. Methods (Duluth) 19:253-269. http://dx.doi.org/10.1006/meth.1999.0855.
52. Kahl CA, Bonnell J, Hiriyanna S, Fultz M, Nyberg-Hoffman C, Chen P, King CR, Gall JG. 2010. Potent immune responses and in vitro proinflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 28:5691-5702. http://dx.doi.org/10.1016/j.vaccine.2010.06.050.
53. Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR, Wei LL. 2008. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis 14:2535-2546.
54. McVey D, Zuber M, Ettyreddy D, Brough DE, Kovesdi I. 2002. Rapid construction of adenoviral vectors by lambda phage genetics. J Virol 76: 3670-3677. http://dx.doi.org/10.1128/JVI.76.8.3670-3677.2002.
55. Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG. 2007. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25:2074-2084. http://dx.doi.org/10.1016/j.vaccine.2006.11.025.
56. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. 1996. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 70:6497-6501.
57. Koelle DM, Reymond SN, Chen H, Kwok WW, McClurkan C, Gyaltsong T, Petersdorf EW, Rotkis W, Talley AR, Harrison DA. 2000. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J Virol 74:10930-10938. http://dx.doi.org/10.1128/JVI.74.23.10930-10938.2000.
58. Koelle DM. 2003. Expression cloning for the discovery of viral antigens and epitopes recognized by T cells. Methods (Duluth) 29:213-226. http://dx.doi.org/10.1016/S1046-2023(02)00344-4.
59. Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, De Rosa SC, Koelle DM, Wald A, Corey L. 2010. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol 30:703-722. http://dx.doi.org/10.1007/s10875-010-9441-2.
60. Rhee EG, Blattman JN, Kasturi SP, Kelley RP, Kaufman DR, Lynch DM, La Porte A, Simmons NL, Clark SL, Pulendran B, Greenberg PD, Barouch DH. 2011. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol 85: 315-323. http://dx.doi.org/10.1128/JVI.01597-10.
61. Stanberry LR, Kern ER, Richards JT, Abbott TM, Overall JC, Jr. 1982. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis 146:397-404. http://dx.doi.org/10.1093/infdis/146.3.397.
62. Muller WJ, Dong L, Vilalta A, Byrd B, Wilhelm KM, McClurkan CL, Margalith M, Liu C, Kaslow D, Sidney J, Sette A, Koelle DM. 2009. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J Gen Virol 90:1153-1163. http://dx.doi.org/10.1099/vir.0.008771-0.
63. Jerome KR, Huang ML, Wald A, Selke S, Corey L. 2002. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 40:2609-2611. http://dx.doi.org/10.1128/JCM.40.7.2609-2611.2002.
64. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RLA, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD, Herpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366: 34-43. http://dx.doi.org/10.1056/NEJMoa1103151.
65. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GlaxoSmithKline Herpes Vaccine Efficacy Study Group. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347:1652-1661. http://dx.doi.org/10.1056/NEJMoa011915.
66. Mertz GJ. 2008. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J Infect Dis 198:1098-1100. http://dx.doi.org/10.1086/591914.
67. Wald A, Bernstein A, Fife K, Lee P, Tyring S, Van Wagoners N, Warren T, Magaret A, Flechtner J, Hetherington S. 2013. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Denver, CO, abstr 183G.
68. Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. 2012. A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 30:7046-7051. http://dx.doi.org/10.1016/j.vaccine.2012.09.057.
69. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L. 2010. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A 107:18973-18978. http://dx.doi.org/10.1073/pnas.1006614107.
70. Tronstein E, Johnston C, Huang M-L, Selke S, Magaret A, Warren T, Corey L, Wald A. 2011. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 305:1441-1449. http://dx.doi.org/10.1001/jama.2011.420.
71. Quinn TC. 2011. Viral kinetics of genital herpes: a molecular probe into host-viral interactions. J Infect Dis 204:495-498. http://dx.doi.org/10.1093/infdis/jir317.
72. Wald A, Zeh J, Selke S, Ashley RL, Corey L. 1995. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 333:770-775. http://dx.doi.org/10.1056/NEJM199509213331205.
73. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, Krieger JN, Corey L. 2000. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 342:844-850. http://dx.doi.org/10.1056/NEJM200003233421203.
74. Schiffer JT, Mayer BT, Fong Y, Swan DA, Wald A. 2014. Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding. J R Soc Interface 11:20140160. http://dx.doi.org/10.1098/rsif.2014.0160.
75. Wald A, Huang ML, Carrell D, Selke S, Corey L. 2003. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 188: 1345-1351. http://dx.doi.org/10.1086/379043.
76. Awasthi S, Shaw C, Friedman H. 2014. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D. Expert Rev Vaccines 13:1475-1488. http://dx.doi.org/10.1586/14760584.2014.951336.
77. Posavad CM, Remington M, Mueller DE, Zhao L, Magaret AS, Wald A, Corey L. 2010. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 184:3250-3259. http://dx.doi.org/10.4049/jimmunol.0900722.
78. Coffman RL, Sher A, Seder RA. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33:492-503. http://dx.doi.org/10.1016/j.immuni.2010.10.002.
79. Shin H, Iwasaki A. 2012. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491:463-467. http://dx.doi.org/10.1038/nature11522.